▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #615 by analyst upside · 2026-11-13
IRD
Opus Genetics, Inc.
Healthcare · Market Cap $392M · P/E 0x
ANALYST PRICE TARGET
+243.4%
implied upside to consensus target
Current Price $4.06
Consensus Target $13.94
Bull Target $20.0
Bear Target $8.0
Analysts Covering 17
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
14
Hold
0
Sell
0
52-Week Low $1.7
52-Week High $7.07
YTD Return +91.5%
FUNDAMENTALS
Market Cap $392M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.48
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $8M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.7
52-Week High $7.07
Current Price $4.06
Bear Target $8.0
Bull Target $20.0
● Now $4.06 ● Target $13.94
TRADING DATA
Avg Volume 2.5M
YTD Return +91.5%
Analyst Count 17
Consensus Buy
Upside to Target +243.4%
Last Updated 2026-11-13

ANALYST SUMMARY

Opus Genetics, Inc. (IRD) is currently trading at $4.06 with a Wall Street consensus price target of $13.94, implying potential upside of 243.4% over the next 12 months. 17 analysts currently cover IRD, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $20.0, while the most cautious has a target of $8.0.

IRD operates in the Healthcare sector with a market capitalisation of $392M. The stock is up 91.5% year-to-date and is currently trading near the lower end of its 52-week range of $1.7 – $7.07.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CRMD +222.3%
CorMedix Inc.
$385M · P/E 2.4x · Strong Buy
XFOR +265.9%
X4 Pharmaceuticals, Inc.
$324M · P/E 5.8x · Buy
PLX +271.6%
Protalix BioTherapeutics, Inc.
$250M · P/E 12.3x · Buy
ASMB +153.7%
Assembly Biosciences, Inc.
$411M · P/E 19.4x · Buy
DTIL +265.7%
Precision BioSciences, Inc.
$307M · P/E 32.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for IRD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital - Reiterated
Buy → Buy 2026-10-22 33% win rate (6 calls)
Citizens reit
Market Outperform → Market Outperform 2026-10-16 Building track record
Jones Trading - Reiterated
Buy → Buy 2026-10-06 57% win rate (14 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-10-02 33% win rate (6 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-09-10 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-09-09 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-09-09 31% win rate (48 calls)
BTIG reit
Buy → Buy 2026-09-09 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
22/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →